Bank of New York Mellon Corp Has $113.34 Million Holdings in Insulet Corporation $PODD

Bank of New York Mellon Corp lessened its position in Insulet Corporation (NASDAQ:PODD) by 2.5% in the 4th quarter, Holdings Channel reports. The fund owned 398,735 shares of the medical instruments supplier’s stock after selling 10,320 shares during the period. Bank of New York Mellon Corp’s holdings in Insulet were worth $113,336,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PODD. Larson Financial Group LLC raised its stake in Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 47 shares during the period. Elyxium Wealth LLC acquired a new stake in shares of Insulet in the fourth quarter worth $28,000. Fideuram Asset Management Ireland dac purchased a new position in shares of Insulet during the fourth quarter valued at $41,000. Measured Wealth Private Client Group LLC purchased a new position in Insulet during the 3rd quarter valued at about $49,000. Finally, Osterweis Capital Management Inc. acquired a new position in shares of Insulet in the 2nd quarter valued at about $51,000.

Insider Transactions at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction on Wednesday, June 3rd. The shares were bought at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.36% of the stock is owned by insiders.

Insulet Price Performance

NASDAQ PODD opened at $153.22 on Monday. Insulet Corporation has a fifty-two week low of $140.63 and a fifty-two week high of $354.88. The stock’s 50-day moving average is $175.73 and its two-hundred day moving average is $238.27. The firm has a market cap of $10.61 billion, a P/E ratio of 35.63, a price-to-earnings-growth ratio of 1.21 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the prior year, the company posted $1.02 EPS. The firm’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, analysts anticipate that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on PODD shares. Rothschild & Co Redburn restated a “neutral” rating and set a $220.00 price target (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Robert W. Baird decreased their target price on shares of Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Evercore lowered their price target on shares of Insulet from $240.00 to $200.00 in a report on Thursday, May 7th. Wells Fargo & Company dropped their price target on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $205.00 price objective on shares of Insulet in a report on Wednesday, May 27th. Twenty-one investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average price target of $252.04.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.